BiotechTube

Tropicamide

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fabry Disease

Conditions

Fabry Disease

Trial Timeline

Aug 1, 2014 → Sep 1, 2016

NCT ID
NCT02023086

About Tropicamide

Tropicamide is a pre-clinical stage product being developed by Sanofi for Fabry Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02023086. Target conditions include Fabry Disease.

Hype Score Breakdown

Clinical
5
Activity
2
Company
9
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT02023086Pre-clinicalCompleted

Competing Products

20 competing products in Fabry Disease

See all competitors
ProductCompanyStageHype Score
LucerastatIdorsiaPhase 3
72
Fabrazyme (agalsidase beta)SanofiPhase 2
51
Venglustat (GZ402671) + PlaceboSanofiPhase 3
76
Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta)SanofiPhase 2
51
agalsidase betaSanofiApproved
84
Fabrazyme (agalsidase beta)SanofiApproved
84
agalsidase betaSanofiApproved
84
AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + FexofenadineSanofiApproved
84
Gabapentin + placeboSanofiPhase 2
51
Agalsidase betaSanofiApproved
84
GZ/SAR402671SanofiPhase 2
51
agalsidase beta (GZ419828) + agalsidase alfaSanofiApproved
84
Fabrazyme (agalsidase beta)SanofiPhase 3
76
Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + MigalastatSanofiPhase 3
76
IohexolSanofiPhase 1
32
GZ/SAR402671SanofiPhase 2
51
Fabrazyme (agalsidase beta)SanofiPhase 2
51
Agalsidase betaSanofiApproved
84
Fabrazyme (agalsidase beta) + PlaceboSanofiApproved
84
Agalsidase beta + Agalsidase betaSanofiPhase 3
76

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84